Ernexa Therapeutics Inc. (ERNA) - Dilution Analysis

10-Q filing | 1.2M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 8,226,000 → 329,040

10-Q filing | 8.2M shares outstanding

10-Q filing | 7.7M shares outstanding

8-K filing: Stock split 1-for-15 | Outstanding: 47,717,087 → 3,181,139

S-3 filing: Selling stockholders are offering 57,049,087 shares of common stock on a resale basis.

8-K filing: Ernexa Therapeutics Inc. completed the second closing of a private placement, issuing 47,717,087 shares of common stock and 9,332,000 pre-funded warrants for approximately $6.0 million in gross proceeds on June 9, 2025. ($12.0M proceeds)

10-Q filing | 62.4M shares outstanding

S-3 filing: Ernexa Therapeutics Inc. is offering 10,443,752 shares of common stock on a resale basis by selling stockholders.

8-K filing: Ernexa Therapeutics Inc. entered into a securities purchase agreement to issue and sell 58,262,918 shares of common stock and pre-funded warrants to purchase up to 11,048,736 shares of common stock in a private placement, with the initial closing on April 2, 2025, involving 9,934,016 shares of common stock and 509,736 pre-funded warrants.

10-K filing | 52.2M shares outstanding

10-Q filing | 51.4M shares outstanding

S-1 filing: This S-1 filing relates to the offering and resale from time to time by the selling stockholders of up to 49,870,566 shares of common stock.

8-K filing: Eterna Therapeutics Inc. entered into a securities purchase agreement for a private placement of common stock, exchange agreements for warrants and convertible notes, and a note purchase agreement for senior convertible notes. ($0.0M proceeds)

10-Q filing | 5.4M shares outstanding

10-Q filing | 5.4M shares outstanding

10-K filing | 5.3M shares outstanding

S-3 filing: This is an S-3 filing for the resale of common stock by selling stockholders, offering up to 18,233,359 shares. The company will not receive any proceeds from the sale of these shares, but may receive proceeds from the exercise of warrants.

8-K filing: Eterna Therapeutics Inc. entered into a securities purchase agreement on December 14, 2023, to sell convertible notes and warrants to accredited investors in a private placement, with an initial closing on December 15, 2023, and a remainder expected by January 15, 2024. ($7.8M proceeds)

10-Q filing | 5.4M shares outstanding

S-3 filing: This S-3 filing relates to the resale of common stock by selling stockholders, with up to 16,754,154 shares being offered.

10-Q filing | 5.3M shares outstanding

8-K filing: Eterna Therapeutics Inc. entered into a Securities Purchase Agreement for a private placement of $8,715,000 in convertible notes and warrants to purchase 6,094,392 shares of common stock.

10-Q filing | 5.1M shares outstanding

8-K filing: Eterna Therapeutics Inc. issued 69,343 shares of common stock to Exacis Biotherapeutics Inc. as part of an asset purchase agreement.

S-1 filing: This S-1 filing relates to the offering of common stock by the selling stockholder, Lincoln Park Capital Fund, LLC, with the company potentially receiving up to $10.0 million in gross proceeds from sales of common stock to the Selling Stockholder.

8-K filing: Eterna Therapeutics Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $10.0 million of the Company's common stock. The company also issued 73,659 shares of common stock to Lincoln Park as a commitment fee.

POS AM filing: This POS AM filing relates to the offering of up to 685,714 shares of common stock by the Selling Stockholder.

10-K filing | 5.1M shares outstanding

10-Q filing | 2.9M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 58,805,000 → 2,940,250

10-Q filing | 58.8M shares outstanding

10-Q filing | 57.5M shares outstanding

S-3 filing: This S-3 filing registers the resale of up to 13,714,284 shares of common stock by selling stockholders.

10-K filing | 57.5M shares outstanding

8-K filing: Brooklyn ImmunoTherapeutics, Inc. completed a private placement of 6,857,142 units, each consisting of one share of common stock (or a pre-funded warrant) and one warrant, for an aggregate purchase price of approximately $12.0 million. ($12.0M proceeds)

8-K filing: A registration statement on Form S-1 was filed with the SEC relating to the proposed public offering by certain selling stockholders of up to 6,281,454 shares of common stock received in connection with the acquisition of Novellus, Inc.

S-1/A filing: This is an S-1/A filing that discloses recent sales of unregistered securities, including shares of common stock issued to Lincoln Park Capital Fund, LLC and in connection with an acquisition agreement.

RW filing: This is a request to withdraw the Form S-3 registration statement, and the company intends to file a registration statement on Form S-1 with respect to the shares of common stock previously intended to be registered pursuant to the Form S-3.

S-1 filing: Resale of common stock previously issued to selling stockholders in connection with the acquisition of Novellus, Inc.

10-Q filing | 50.5M shares outstanding

S-3 filing: This S-3 filing registers 6,281,454 shares of common stock for resale by selling stockholders who acquired the shares in connection with the acquisition of Novellus, Inc. The company will not receive any proceeds from the sale of these shares.

10-Q filing | 51.7M shares outstanding

8-K filing: Brooklyn ImmunoTherapeutics acquired Novellus, Inc. through a merger, issuing 7,022,230 shares of common stock valued at $102,000,000 as part of the $125,000,000 consideration. ($102.0M proceeds)

S-1 filing: The filing relates to the offer and sale of up to 2,869,881 shares of common stock by Lincoln Park Capital Fund, LLC, including shares issued as consideration and shares that may be purchased under a purchase agreement for up to $40,000,000.

8-K filing: The company entered into a purchase agreement with Lincoln Park Capital Fund, LLC, under which the company may sell up to $40.0 million of shares of common stock.

10-Q filing | 41.5M shares outstanding

S-1 filing: The filing is for the offer and sale from time to time of up to 1,379,668 shares of common stock by Lincoln Park Capital Fund, LLC, with the company potentially selling shares to the selling stockholder for a total purchase price of up to $20,000,000.

8-K filing: The company entered into a purchase agreement with Lincoln Park Capital Fund, LLC, under which the company may sell up to $20.0 million of shares of common stock. Upon entering into the Purchase Agreement, the company issued and sold 56,041 shares of common stock to Lincoln Park as consideration for Lincoln Park's commitment.

8-K filing: Stock split 1-for-2 | Outstanding: 2,976,774 → 41,514,166

10-K filing | 3.0M shares outstanding

10-Q filing | 2.9M shares outstanding

10-Q filing | 2.9M shares outstanding

10-Q filing | 2.9M shares outstanding

10-K filing | 2.9M shares outstanding